These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28791783)

  • 1. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
    Zeineddine HA; Girard R; Cao Y; Hobson N; Fam MD; Stadnik A; Tan H; Shen J; Chaudagar K; Shenkar R; Thompson RE; McBee N; Hanley D; Carroll T; Christoforidis GA; Awad IA
    J Magn Reson Imaging; 2018 Apr; 47(4):1133-1138. PubMed ID: 28791783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
    Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee NA; Treine K; Ostapkovich N; Wang Y; Thompson RE; Koenig JI; Carroll T; Hanley DF; Awad IA
    Stroke; 2024 Jan; 55(1):31-39. PubMed ID: 38134265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
    Girard R; Fam MD; Zeineddine HA; Tan H; Mikati AG; Shi C; Jesselson M; Shenkar R; Wu M; Cao Y; Hobson N; Larsson HBW; Christoforidis GA; Awad IA
    J Neurosurg; 2017 Jul; 127(1):102-110. PubMed ID: 27494817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.
    Tan H; Liu T; Wu Y; Thacker J; Shenkar R; Mikati AG; Shi C; Dykstra C; Wang Y; Prasad PV; Edelman RR; Awad IA
    Invest Radiol; 2014 Jul; 49(7):498-504. PubMed ID: 24619210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
    Polster SP; Stadnik A; Akers AL; Cao Y; Christoforidis GA; Fam MD; Flemming KD; Girard R; Hobson N; Koenig JI; Koskimäki J; Lane K; Liao JK; Lee C; Lyne SB; McBee N; Morrison L; Piedad K; Shenkar R; Sorrentino M; Thompson RE; Whitehead KJ; Zeineddine HA; Hanley DF; Awad IA
    Neurosurgery; 2019 Dec; 85(6):843-853. PubMed ID: 30476251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
    Tan H; Zhang L; Mikati AG; Girard R; Khanna O; Fam MD; Liu T; Wang Y; Edelman RR; Christoforidis G; Awad IA
    AJNR Am J Neuroradiol; 2016 Jul; 37(7):1209-15. PubMed ID: 26965464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative susceptibility mapping (QSM) as a means to monitor cerebral hematoma treatment.
    Zhang Y; Wei H; Sun Y; Cronin MJ; He N; Xu J; Zhou Y; Liu C
    J Magn Reson Imaging; 2018 Oct; 48(4):907-915. PubMed ID: 29380461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.
    Carrión-Penagos J; Zeineddine HA; Polster SP; Girard R; Lyne SB; Koskimäki J; Romanos S; Srinath A; Zhang D; Cao Y; Stadnik A; Piedad K; Shenkar R; Awad IA
    J Neurosurg; 2021 Mar; 134(3):1147-1154. PubMed ID: 32244216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
    Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar R; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee N; Treine K; Ostapkovich N; Wang Y; Thompson RE; Mendoza-Puccini C; Koenig J; Carroll T; Hanley DF; Awad IA
    medRxiv; 2023 Jun; ():. PubMed ID: 37333396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
    Girard R; Li Y; Stadnik A; Shenkar R; Hobson N; Romanos S; Srinath A; Moore T; Lightle R; Shkoukani A; Akers A; Carroll T; Christoforidis GA; Koenig JI; Lee C; Piedad K; Greenberg SM; Kim H; Flemming KD; Ji Y; Awad IA
    Neurosurgery; 2021 Feb; 88(3):686-697. PubMed ID: 33469662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project.
    Kim H; Flemming KD; Nelson JA; Lui A; Majersik JJ; Cruz MD; Zabramski J; Trevizo O; Lanzino G; Zafar A; Torbey M; Mabray MC; Robinson M; Narvid J; Lupo J; Thompson RE; Hanley DF; McBee N; Treine K; Ostapkovich N; Stadnik A; Piedad K; Hobson N; Carroll T; Shkoukani A; Carrión-Penagos J; Mendoza-Puccini C; Koenig JI; Awad I
    Stroke; 2021 Dec; 52(12):3829-3838. PubMed ID: 34525838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid quantitative susceptibility mapping of intracerebral hemorrhage.
    De A; Sun H; Emery DJ; Butcher KS; Wilman AH
    J Magn Reson Imaging; 2020 Mar; 51(3):712-718. PubMed ID: 31276278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliable? The Value of Early Postoperative Magnetic Resonance Imaging after Cerebral Cavernous Malformation Surgery.
    Chen B; Göricke S; Wrede K; Jabbarli R; Wälchli T; Jägersberg M; Sure U; Dammann P
    World Neurosurg; 2017 Jul; 103():138-144. PubMed ID: 28391022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative susceptibility mapping across two clinical field strengths: Contrast-to-noise ratio enhancement at 1.5T.
    Ippoliti M; Adams LC; Winfried B; Hamm B; Spincemaille P; Wang Y; Makowski MR
    J Magn Reson Imaging; 2018 Nov; 48(5):1410-1420. PubMed ID: 29659131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic susceptibility as a 1-year predictor of outcome in familial cerebral cavernous malformations: a pilot study.
    Incerti I; Fusco M; Contarino VE; Siggillino S; Conte G; Lanfranconi S; Bertani GA; Gaudino C; d'Orio P; Pallini R; D'Alessandris QG; Meessen JMTA; Nicolis EB; Vasamì A; Dejana E; Bianchi AM; Triulzi FM; Latini R; Scola E
    Eur Radiol; 2023 Jun; 33(6):4158-4166. PubMed ID: 36602570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration.
    Li J; Lin H; Liu T; Zhang Z; Prince MR; Gillen K; Yan X; Song Q; Hua T; Zhao X; Zhang M; Zhao Y; Li G; Tang G; Yang G; Brittenham GM; Wang Y
    J Magn Reson Imaging; 2018 Oct; 48(4):1069-1079. PubMed ID: 29566449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zabramski classification in predicting the occurrence of symptomatic intracerebral hemorrhage in sporadic cerebral cavernous malformations.
    Wang J; Yu QF; Huo R; Sun YF; Jiao YM; Xu HY; Zhang JZ; Zhao SZ; He QH; Wang S; Zhao JZ; Cao Y
    J Neurosurg; 2024 Mar; 140(3):792-799. PubMed ID: 37724811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preconditioned total field inversion (TFI) method for quantitative susceptibility mapping.
    Liu Z; Kee Y; Zhou D; Wang Y; Spincemaille P
    Magn Reson Med; 2017 Jul; 78(1):303-315. PubMed ID: 27464893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.
    Hobson N; Polster SP; Cao Y; Flemming K; Shu Y; Huston J; Gerrard CY; Selwyn R; Mabray M; Zafar A; Girard R; Carrión-Penagos J; Chen YF; Parrish T; Zhou XJ; Koenig JI; Shenkar R; Stadnik A; Koskimäki J; Dimov A; Turley D; Carroll T; Awad IA
    J Magn Reson Imaging; 2020 Apr; 51(4):1192-1199. PubMed ID: 31515878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.
    Girard R; Zeineddine HA; Koskimäki J; Fam MD; Cao Y; Shi C; Moore T; Lightle R; Stadnik A; Chaudagar K; Polster S; Shenkar R; Duggan R; Leclerc D; Whitehead KJ; Li DY; Awad IA
    Circ Res; 2018 Jun; 122(12):1716-1721. PubMed ID: 29720384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.